Fig. 1.

Identification of eIF6 as a prognostic factor in LUAD based on bioinformatic analysis. (A) Boxplot of the TCGA-LUAD dataset showing differential eIF6 mRNA expression in normal and tumor samples. The level eIF6 mRNA expression is higher in tumor samples compared with that in normal tissues in both the (B) GSE81809 (normal, n = 19; tumor, n = 199) and (B) GSE68465 (normal, n = 19; tumor, n = 443) GEO datasets. (D) No significant difference in eIF6 mRNA expression could be observed after stratification by ethnicity. Higher eIF6 mRNA levels were significantly associated with the (E) TP53-mutation genotype, (F) lymphatic metastasis and (G) pathological stages. (H) Kaplan-Meier analysis suggested that patients with higher eIF6 expression levels had shorter overall survival compared with those with lower eIF6 expression levels, according to log-rank test (TCGA-LUAD cohort; n = 504; P = 0.00045). ^***P < 0.001. eIF6, eukaryotic translation initiation factor 6; LUAD, lung adenocarcinoma; TCGA, The Cancer Genome Atlas; GEO, Gene Expression Omnibus